AFM
LFCR icon

Anson Funds Management’s Lifecore Biomedical LFCR Stock Holding History

Anson Funds Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-475,062
Closed -$1.79M – 171
2023
Q1 		$1.79M Buy
+475,062
New +$2.65M 0.29% 72

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Anson Funds Management's LFCR Position: Q2 2023 in Review

Anson Funds Management sold out of Lifecore Biomedical (LFCR) in Q2 2023, closing a stake of 475,062 shares — an estimated $1.79M sold.

Anson Funds Management first reported a position in LFCR in Q1 2023 and held it in 1 quarter. The position peaked at $1.79M in Q1 2023. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2023.

  • Anson Funds Management reported no remaining Lifecore Biomedical position as of Q2 2023 after selling out during the quarter.
  • Anson Funds Management sold 475,062 Lifecore Biomedical shares in Q2 2023, an estimated $1.79M.
  • Anson Funds Management first reported a position in Lifecore Biomedical in Q1 2023 and held it in 1 quarter.
  • Anson Funds Management's Lifecore Biomedical position peaked at $1.79M in Q1 2023.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2023.

Based on Anson Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.